Table 2 Baseline clinical and viro-immunological characteristics of 67 HIV-infected naive pregnant women with valuable results from the HIV genotypic drug-resistance assay
Characteristics | HIV-infected pregnant women with a valuable result at HIV genotype n° 67 | p value | |
|---|---|---|---|
Women with wild-type genotype n° 59 | Women with any drug-resistant mutation n°8 | ||
Age, years, mean ± SD | 28.6 ± 5.3 | 30.6 ± 4.7 | 0.3 |
Gestational age at enrolment, week, mean ± SD; | 20.8 ± 4.9 | 17.2 ± 4.4 | 0.06 |
Height at screening, cm, mean ± SD | 155.9 ± 5.9 | 155.3 ± 3.2 | 0.8 |
Race/ethnicity, | |||
Black African, n. (%) | 59 (100) | 8 (100) | 1 |
Education, n. (%) | 0.3 | ||
Primary school | 36 (61) | 7 (87.5) | |
Secondary school | 10 (16.9) | 1 (12.5) | |
Other or unknown | 13 (22) | 0 (0) | |
Number of pregnancies, mean ± SD | 2.9 ±1.5 | 2.6 ±1.8 | 0.6 |
Number of deliveries, mean ± SD | 1.8 ±1.5 | 1.6 ±1.8 | 0.7 |
Number of children, mean ± SD | 1.4 ±1.2 | 1.6 ±1.8 | 0.6 |
HIV risk factor, n° (%) | |||
Unprotected heterosexual relationship | 59 (100) | 8 (100) | 1 |
WHO stage, n° (%) | 0.9 | ||
1 | 35 (59) | 4 (50) | |
2 | 15 (25) | 3 (37.5) | |
3 | 8 (14) | 1 (12.5) | |
4 | 1 (2) | 0 | |
MedianCD4+ cells at enrolment /μL (IQR) | 406 (297-530) | 396 (240-461) | 0.7 |
Days since HIV diagnosis, mean ± SD | 102 ±182 | 117 ±28 | 0.8 |
Median log10 HIV RNA copies/mL (IQR) | 9.28 (4.82-10.71) | 7.94 (3.58-9.49) | 0.3 |
Eligible for HAART, n (%) | 9 (15.5) | 2 (25) | 0.5 |
Positive VDRL assay, n (%) | 1 (1.9) | 1 (12.5) | 0.1 |